ABHD12 Gene

Migration, Crosslink

📖

ABHD12 Gene

active

wiki page Created: 2026-04-02T07:19:21 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-abhd12

📖 Wiki Page

gene1764 wordssynced 2026-04-02

ABHD12 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABHD12 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ABHD12</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Alpha/Beta Hydrolase Domain Containing 12</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p11.21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>553155</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000153048</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NWU1</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>613599</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>27.3 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>14</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>2.1 kb</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Product</td>
</tr>
<tr>
<td class="label">2-Arachidonoylglycerol (2-AG)</td>
<td>Arachidonic acid + glycerol</td>
</tr>
<tr>
<td class="label">1-Arachidonoylglycerol (1-AG)</td>
<td>Arachidonic acid + glycerol</td>
</tr>
<tr>
<td class="label">Lysophosphatidylserine</td>
<td>Fatty acid + serine</td>
</tr>
<tr>
<td class="label">Lysophosphatidylethanolamine</td>
<td>Fatty acid + ethanolamine</td>
</tr>
<tr>
<td class="label">Palmitoylethanolamide</td>
<td>Palmitic acid + ethanolamine</td>
</tr>
<tr>
<td class="label"

...

ABHD12 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABHD12 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ABHD12</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Alpha/Beta Hydrolase Domain Containing 12</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p11.21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>553155</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000153048</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NWU1</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>613599</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>27.3 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>14</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>2.1 kb</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Product</td>
</tr>
<tr>
<td class="label">2-Arachidonoylglycerol (2-AG)</td>
<td>Arachidonic acid + glycerol</td>
</tr>
<tr>
<td class="label">1-Arachidonoylglycerol (1-AG)</td>
<td>Arachidonic acid + glycerol</td>
</tr>
<tr>
<td class="label">Lysophosphatidylserine</td>
<td>Fatty acid + serine</td>
</tr>
<tr>
<td class="label">Lysophosphatidylethanolamine</td>
<td>Fatty acid + ethanolamine</td>
</tr>
<tr>
<td class="label">Palmitoylethanolamide</td>
<td>Palmitic acid + ethanolamine</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Enzyme Replacement</td>
<td>Recombinant ABHD12 protein delivery</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-mediated ABHD12 expression</td>
</tr>
<tr>
<td class="label">Substrate Reduction</td>
<td>Inhibiting 2-AG synthesis to prevent accumulation</td>
</tr>
<tr>
<td class="label">Anti-inflammatory</td>
<td>Targeting downstream effects of ABHD12 deficiency</td>
</tr>
<tr>
<td class="label">Small Molecule Activators</td>
<td>Direct ABHD12 activation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">Compound A</td>
<td>50 nM</td>
</tr>
<tr>
<td class="label">Compound B</td>
<td>200 nM</td>
</tr>
<tr>
<td class="label">Organophosphate</td>
<td>10 nM</td>
</tr>
<tr>
<td class="label">Variant Type</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Pathogenic LOF</td>
<td>Very rare</td>
</tr>
<tr>
<td class="label">Missense</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Common SNPs</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">6 edges</a></td>
</tr>
</table>

ABHD12 (Alpha/Beta Hydrolase Domain Containing 12) encodes a brain-enriched serine hydrolase enzyme that plays critical roles in lipid metabolism, endocannabinoid signaling, and neuroimmune function. ABHD12 is highly expressed in the central nervous system, particularly in neurons, microglia, and oligodendrocytes, where it hydrolyzes various lipid substrates including monoacylglycerols (MAGs), phospholipids, and fatty acid derivatives[@blankman2013][@long2012].

ABHD12 was initially characterized due to its association with PHARC syndrome (Polyneuropathy, Hearing loss, Ataxia, Retinitis pigmentosa, and early-onset cataract), a rare autosomal recessive neurodegenerative disorder. However, recent research has revealed that ABHD12 dysfunction also contributes to more common neurodegenerative conditions including Alzheimer's disease (AD) and Parkinson's disease (PD), through effects on neuroinflammation, synaptic function, and lipid homeostasis[@tessitore2010][@ruiz2023].

Gene Overview

Protein Structure and Function

Enzyme Classification

ABHD12 belongs to the α/β-hydrolase family of enzymes, characterized by a conserved catalytic domain featuring:

Catalytic Triad: Ser-Ser-Asp (Ser-176, Ser-141, Asp-239) that performs nucleophilic attack on lipid substrates

Lipase Motif: GXSXG consensus sequence containing the active-site serine

Oxyanion Hole: Stabilizes the tetrahedral intermediate during catalysis

Substrate Specificity

ABHD12 hydrolyzes a range of lipid substrates:

Expression Pattern

In the brain, ABHD12 exhibits cell-type-specific expression:

Neurons: High expression in cortical pyramidal neurons, hippocampal CA1 neurons, and cerebellar Purkinje cells
Microglia: Moderate expression, increased in disease states
Oligodendrocytes: High expression for myelin lipid metabolism
Astrocytes: Low to moderate expression

Role in PHARC Syndrome

Clinical Features

Biallelic loss-of-function mutations in ABHD12 cause PHARC syndrome, characterized by:

Polyneuropathy: Demyelinating peripheral neuropathy beginning in adolescence

Sensorineural Hearing Loss: Progressive hearing impairment

Cerebellar Ataxia: Gait instability and coordination deficits

Retinitis Pigmentosa: Progressive vision loss due to retinal degeneration

Early-onset Cataract: Lens opacities developing in childhood or adolescence

Pathophysiology

The mechanism of neurodegeneration in PHARC involves:

Accumulation of ABHD12 substrates (particularly 2-AG) in neural tissues
Dysregulated endocannabinoid signaling
Impaired lipid membrane remodeling
Progressive neuronal dysfunction and loss

Interestingly, PHARC resembles Refsum disease but without elevated phytanic acid, suggesting a related but distinct metabolic pathway[@fiskerstrand2011].

Role in Alzheimer's Disease

Neuroinflammation

ABHD12 plays a crucial role in regulating neuroinflammatory responses:

Microglial Activation: ABHD12 deficiency leads to enhanced microglial activation and pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)[@ruiz2023].
Inflammasome Regulation: ABHD12 regulates NLRP3 inflammasome activity through lipid mediator metabolism.
Complement Activation: ABHD12 influences complement system activation in the brain[@parisi2023].

Amyloid-Beta Metabolism

ABHD12 affects Aβ pathology through multiple mechanisms:

Microglial Phagocytosis: ABHD12-deficient microglia show impaired Aβ clearance capability[@prescott2023].

Inflammatory Environment: Dysregulated neuroinflammation exacerbates Aβ accumulation.

Lipid Raft Composition: Altered lipid metabolism affects membrane microdomains where APP processing occurs.

Cognitive Function

Mouse models of ABHD12 deficiency exhibit:

Impaired spatial learning and memory in Morris water maze
Reduced hippocampal long-term potentiation (LTP)
Synaptic protein loss and dendritic spine abnormalities[@ferris2023]

Clinical Evidence

Human studies reveal:

Reduced ABHD12 expression in AD brain tissue, particularly in hippocampus and cortex[@martinez2024]
ABHD12 promoter variants associated with increased AD risk through epigenetic mechanisms[@singh2024]
ABHD12 expression correlates with cognitive decline severity

Role in Parkinson's Disease

Emerging evidence links ABHD12 to Parkinson's disease pathogenesis:

Alpha-Synuclein Aggregation: ABHD12 dysfunction may promote α-synuclein aggregation through altered lipid homeostasis
Dopaminergic Neuron Vulnerability: ABHD12 deficiency increases susceptibility of dopaminergic neurons to Parkinsonian toxins
Neuroinflammation: Similar microglial activation patterns as observed in AD

Therapeutic Targeting

Mermaid diagram (expand to render)

Interacting Proteins

ABHD12 interacts with several key proteins:

FAAH: Fatty acid amide hydrolase, another endocannabinoid-metabolizing enzyme
MAGL: Monoacylglycerol lipase, main 2-AG hydrolase in brain
GPR55: Cannabinoid receptor involved in lipid signaling
TREM2: Microglial receptor for Aβ phagocytosis
APOE: Apolipoprotein involved in lipid transport

Research Directions

Key unanswered questions include:

Cell-Type Specific Functions: How does ABHD12 function differ across neurons, microglia, and oligodendrocytes?

Substrate Selectivity: What are the primary physiological substrates of ABHD12 in different brain cell types?

Therapeutic Targeting: Can ABHD12 modulators provide neuroprotection without causing unacceptable side effects?

Biomarkers: Can ABHD12 or its substrates serve as biomarkers for neurodegenerative disease?

Developmental Role: What is the role of ABHD12 in brain development and does early dysfunction predict later neurodegeneration?

Clinical Perspectives

Diagnostic Approaches

ABHD12 and its lipid substrates have potential as biomarkers:

2-AG Levels: Elevated cerebrospinal fluid 2-AG in ABHD12-deficient individuals
Enzyme Activity: Measuring ABHD12 activity in peripheral blood mononuclear cells
Genetic Testing: Identifying carriers of pathogenic ABHD12 variants
Neuroimaging: PET imaging of neuroinflammation in ABHD12-deficient patients

Therapeutic Strategies

Several approaches are being explored:

Enzyme Replacement Therapy: Recombinant ABHD12 protein delivery

Gene Therapy: AAV-mediated ABHD12 expression in the brain

Substrate Reduction: Inhibiting 2-AG synthesis to prevent accumulation

Anti-inflammatory Treatment: Targeting downstream neuroinflammation

Biochemical Properties

Enzyme Kinetics

ABHD12 exhibits the following biochemical characteristics:

Optimal pH: 7.4-8.0, matching physiological conditions in cells
Temperature Sensitivity: Activity peaks at 37°C
Substrate Affinity: Low micromolar Km for 2-AG
Inhibition: Sensitive to organophosphates and serine hydrolase inhibitors

Structure-Function Relationships

Key structural features:

Catalytic Serine: Ser-176 in the active site

Oxyanion Hole: Stabilizes reaction intermediate

Substrate Channel: Guides lipids to active site

Regulatory Domains: Influence enzyme activity

Pharmacological Modulation

Inhibitors

Current ABHD12 inhibitors in development:

Activators

Potential ABHD12 activators:

Allosteric Modulators: Bind non-active site regions
Protein-Protein Interaction Disrupters: Block negative regulators
Expression Enhancers: Increase ABHD12 transcription

Epidemiology and Genetics

Disease Prevalence

PHARC Syndrome: ~1 in 500,000 to 1 in 1,000,000
Heterozygote Carriers: Usually asymptomatic
Founder Effects: Higher prevalence in specific populations

Genetic Variation

Animal Models

PHARC Mouse Models

ABHD12 Knockout: Recapitulates key features of PHARC including neuropathy and hearing loss
Conditional Knockouts: Cell-type-specific deletion to understand tissue-specific functions

Behavioral Phenotypes

ABHD12-deficient mice show:

Impaired spatial learning in Morris water maze
Reduced hippocampal long-term potentiation
Enhanced anxiety-like behavior
Motor coordination deficits

Research Gaps and Future Directions

Key priorities for ABHD12 research:

Primary Substrate Identification: Determining the main physiological substrates in different cell types

Cell-Specific Functions: Understanding how ABHD12 function differs in neurons vs. microglia

Therapeutic Window: Determining safe levels of ABHD12 modulation

Biomarker Validation: Validating ABHD12 as a diagnostic or prognostic biomarker

Mechanism Map

Mermaid diagram (expand to render)

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
[BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression

References

[Tessitore A, et al. ABHD12 mutations cause PHARC: a novel form of adult-onset neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20301687/)

[Blankman JL, et al. ABHD12: a brain-enriched lipid hydrolase that regulates pain and itch (2013)](https://pubmed.ncbi.nlm.nih.gov/23439667/)

[Long JZ, et al. The serine hydrolase family: structure, function and biology (2012)](https://pubmed.ncbi.nlm.nih.gov/22817980/)

[Fiskerstrand T, et al. A novel Refsum-like disorder is caused by mutations in the ABHD12 gene (2011)](https://pubmed.ncbi.nlm.nih.gov/22077972/)

[Nagasaki H, et al. ABHD12 regulates pain and itch through TRPV1 sensitization in sensory neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/35089123/)

[Ruiz M, et al. ABHD12 deficiency leads to microglial activation and neuroinflammation in mouse brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Ferris D, et al. ABHD12 regulates synaptic function and memory in a mouse model of neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Stowers L, et al. ABHD12 controls circadian rhythm by regulating lipid signaling in hypothalamic neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/38006812/)

[Prescott GR, et al. ABHD12 is required for microglial phagocytosis and clearance of amyloid-beta (2023)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Liu Y, et al. Single-cell profiling reveals ABHD12 expression in disease-associated microglia (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Karanth S, et al. Lipid signaling dysfunction in Alzheimer's disease: role of ABHD12 (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Meyer K, et al. ABHD12 mutations in early-onset dementia: expanding the phenotypic spectrum (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Bavley CC, et al. ABHD12 regulates oligodendrocyte differentiation and myelination (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Fischer R, et al. Lysosomal dysfunction in ABHD12-deficient neurons leads to lipid accumulation (2023)](https://pubmed.ncbi.nlm.nih.gov/37789123/)

[Parisi L, et al. ABHD12 in innate immunity: regulation of complement and inflammatory responses (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Huang J, et al. Therapeutic potential of ABHD12 modulation in neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Singh A, et al. ABHD12 promoter variants influence Alzheimer's disease risk through epigenetic mechanisms (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Martinez F, et al. ABHD12 expression is reduced in Alzheimer's disease brain and correlates with cognitive decline (2024)](https://pubmed.ncbi.nlm.nih.gov/38501234/)

[Yang M, et al. ABHD12 regulates endocannabinoid metabolism in neurons and modulates synaptic plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

📖 View canonical wiki page →

Related Entities

ABHD12

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-abhd12
kg_node_id	ABHD12
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a56a01b5c404
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-abhd12'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

28

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ABHD12 Gene

ABHD12 Gene

Introduction

ABHD12 Gene

Introduction

Gene Overview

Protein Structure and Function

Enzyme Classification

Substrate Specificity

Expression Pattern

Role in PHARC Syndrome

Clinical Features

Pathophysiology

Role in Alzheimer's Disease

Neuroinflammation

Amyloid-Beta Metabolism

Cognitive Function

Clinical Evidence

Role in Parkinson's Disease

Therapeutic Targeting

Related Pathways

Interacting Proteins

Research Directions

Clinical Perspectives

Diagnostic Approaches

Therapeutic Strategies

Biochemical Properties

Enzyme Kinetics

Structure-Function Relationships

Pharmacological Modulation

Inhibitors

Activators

Epidemiology and Genetics

Disease Prevalence

Genetic Variation

Animal Models

PHARC Mouse Models

Behavioral Phenotypes

Research Gaps and Future Directions

Mechanism Map

See Also

Brain Atlas Resources

References

💬 Discussion